Sars cov 2 igg scovg

All samples were tested using the following four SARS-CoV-2 binding antibody assays: Elecsys Anti-SARS-CoV-2 S (Roche Diagnostics, Basel, Switzerland), SARS-CoV-2 IgG (sCOVG) (Siemens, Munich, Germany), AdvanSure SARS-CoV-2 IgG (RBD) ELISA (LG Chem, Seoul, Korea), and AdvanSure SARS-CoV-2 IgG (S1) ELISA (LG Chem, Seoul, Korea). The former two are CLIAs, and the latter two are ELISAs. Detailed descriptions of the assay kits are presented in Table A2(B). All assays were performed according to the manufacturers’ instructions. For the Roche and Siemens assay kits, the samples were retested after an additional dilution step if the values obtained exceeded the analytical measurement interval. According to the WHO international standard for anti-SARS-CoV-2 immunoglobulin, traceable units of bound antibody per milliliter (BAU/mL) were calculated using conversion factors (Roche 1.208: Siemens 21.803). The binding antibody levels obtained by serological PRNT and sVNT were compared using serial serum samples from vaccine recipients.

The serum samples and the first WHO International standard were also tested to determine the antibody titer against SARS‐CoV‐2 antigens, using:

The Elecsys Anti‐SARS‐CoV‐2 (Roche Diagnostics, Inc.), a high‐throughput ECLIA qualitative method to detect Pan‐Ig against the Nucleocapsid protein.

The Elecsys Anti‐SARS‐CoV‐2 S (Roche Diagnostics, Inc.), a high‐throughput ECLIA qualitative and semi‐quantitative method to detect Pan‐Ig against the spike RBD.

The SARS‐CoV‐2 IgG (sCOVG) (Siemens Healthcare Diagnostics Inc.), a high‐throughput CLIA qualitative and semi‐quantitative approach to detect IgG against the spike RBD.

The CHORUS SARS‐CoV‐2 “NEUTRALIZING” Ab (DIESSE Diagnostica Senese SpA), an immunoenzymatic method for the quantitative detection of Pan‐Ig against the spike (S1) protein.

The characteristics of the diagnostic serological tests are listed in Table 2.